

## Thymidylate Synthase Promoter Polymorphism, Interaction with Folate Intake, and Risk of Colorectal Adenomas

Cornelia M. Ulrich,<sup>1</sup> Jeannette Bigler, Roberd Bostick, Lisa Fosdick, and John D. Potter

Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 [C. M. U., J. B., J. D. P.]; Department of Epidemiology, University of Washington, Seattle, Washington 98195 [C. M. U., J. D. P.]; University of Minnesota, Minneapolis, Minnesota 55414 [L. F.]; and University of South Carolina, Columbia, South Carolina 29208 [R. B.]

### Abstract

Thymidylate synthase (TS) is a key enzyme in folate metabolism and the primary target of 5-fluorouracil. A repeat polymorphism in the TS promoter enhancer region (2rpt versus 3rpt of 28 bp) is associated with decreased expression, and a 6-bp deletion in the 3'untranslated region may affect RNA stability. We investigated the role of TS polymorphisms in a case control study of adenomatous polyps (510 cases and 604 polyp-free controls). Multivariate-adjusted odds ratios (ORs; 95% confidence interval) for *TSER* 2rpt/3rpt and 2rpt/2rpt compared with 3rpt/3rpt were 0.8 (0.6–1.2) and 0.9 (0.6–1.3), respectively. We observed a significant gene-nutrient interaction between the *TSER* polymorphism and folate intake: among 3rpt/3rpt individuals (greater expression), folate intake > 440 µg/day (highest tertile) versus ≤440 µg/day was associated with a 2-fold decreased risk [ORs 1.0 (reference group) versus 0.5 (0.3–0.9)]. However, among 2rpt/2rpt individuals, high folate intake was associated with a 1.5-fold increased risk [ORs 0.6 (0.4–0.9) versus 0.9 (0.5–1.5; *P* for interaction = 0.03)]. Vitamin B<sub>12</sub> showed a similar trend (*P* = 0.08). No clear pattern was seen with the *TS* 1494del6 polymorphism. These findings raise questions regarding the molecular pathways linking folate metabolism and colorectal carcinogenesis, including whether high folate is beneficial in the presence of all metabolic genotypes.

### Introduction

TS<sup>2</sup> is a key enzyme in folate metabolism and catalyzes the conversion of dUMP to dTMP. This conversion is essential for the provision of thymidine, a nucleotide needed for DNA synthesis and repair. TS is also a target for major chemotherapeutic drugs, including 5-fluorouracil. The substrate for TS, 5,10-methylene-THF, is a central metabolite in folate metabolism and is diverted into different pathways, including thymidine synthesis, purine synthesis, and toward the provision of methyl groups for DNA methylation. Colon cells are subject to rapid turnover and, thus, are the site of high rates of DNA synthesis. Furthermore, DNA repair is essential in the colonic environment, and DNA repair mechanisms can be affected by nucleotide availability (1–3). Folate deficiency has been shown to increase several measures of DNA damage (4, 5), and a low folate status is consistently associated with an increased risk of colorectal cancer (6, 7). The human *TS* promoter region includes several mechanisms for gene regulation, including a *cis*-acting enhancer element (8). This *TSER* is polymorphic, containing two or three 28-bp tandem repeats among Caucasian and Asian populations (9, 10). The less common double repeat is associated with 2.6-fold lower TS expression in

HeLaS3 cells than the triple repeat (9), and *in vivo* TS mRNA levels in tumor tissue were 3.6-fold lower among 2rpt/2rpt individuals compared with 3rpt/3rpt individuals (11). We also reported recently on a second *TS* polymorphism, a 6-bp deletion at bp 1494 in the 3'UTR that may be associated with decreased mRNA levels in colorectal tumors (12, 13). We hypothesized that a change in *TS* expression may affect colon carcinogenesis and investigated the risk of colorectal adenomas associated with the two *TS* polymorphisms in a large case control study of colonoscopically screened men and women.

### Materials and Methods

**Study Subjects.** Subject recruitment for the Minnesota Cancer Prevention Research Unit case control study has been described previously (14). Briefly, cases and controls were recruited through a multiclinic private gastroenterology practice in metropolitan Minneapolis, Digestive Healthcare. Patients (age 30–74 years) who were scheduled for colonoscopy between April 1991 and April 1994 were screened for eligibility and recruited prior to colonoscopy. Recruitment at all 10 sites was initiated at the time of scheduling with the intention of recruiting subjects with both patient and recruiter blind to the final diagnosis. The study protocol was approved by the internal review boards of the University of Minnesota, and each DH endoscopy site and written informed consent was given by each study participant.

Eligibility criteria for both cases and controls were: (a) resident of Twin cities metropolitan area; (b) age 30–74 years; (c) English speaking; (d) no known genetic syndrome associated with colonic neoplasia; and (e) no history of cancer (except nonmelanoma skin cancer), adenomatous polyps, or inflammatory bowel disease. Indications for colonoscopy have been published previously (15), and 68% of all colonoscoped patients participated.

At the colonoscopy visit, questionnaires were collected, blood was drawn, and the colonoscopy findings were recorded. Only participants with a complete colonoscopy reaching the cecum were eligible. All polyps were removed and evaluated histologically. Patients with polyps showing invasive carcinoma were not included. Adenomatous polyp cases are those found to have ≥1 adenomatous polyp; controls were polyp free at colonoscopy.

**Data Collection.** Data collection included information on dietary intake, physical activity, smoking habits, anthropometric measurements, medical information, demographic information, and reproductive history. When data were incomplete, study staff followed up by phone. The dietary questionnaire was an adaptation of the Willett food-frequency questionnaire, which has been studied previously for validity and repeatability. Furthermore, folate values derived from this questionnaire correlated with RBC folate levels (an indicator of long-term folate status *r* = 0.56).

**Genotyping.** Genomic DNA from lymphocytes was extracted using the PureGene kit (Gentra Systems, Inc., Minneapolis, MN). For the analysis of the *TSER* 28-bp repeat polymorphism, a fragment containing the repeats was amplified using primers TS forward primer: 5'-GTGGCTCCTCGGTTTC-CCCC-3' and TS reverse primer: 5'-GGCTCCGAGCCGGCCACAGGCATG-GCGCGG-3' (9). The PCR reactions contained 1 × GeneAmp buffer (Applied Biosystems, Foster City, CA), 1.5 mM MgCl<sub>2</sub>, 200 µM deoxyribonucleotide triphosphates, 100 nM each primer, 10% DMSO, 1 unit of AmpliTaq DNA polymerase (Applied Biosystems), and 100 ng of genomic DNA. Cycling conditions were one cycle of 94°C for 2 min, 35 cycles of 94°C for 30 s, 63°C for 30 s, and 72°C for 30 s, and a final extension at 72°C for 5 min. The

Received 3/18/02; accepted 4/23/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> To whom requests for reprints should be addressed, at Fred Hutchinson Cancer Research Center, Cancer Prevention Research Program, 1100 Fairview Avenue N, MP-900, Seattle, WA 98109-1024. Phone: (206) 667-7617; Fax: (206) 667-7850; E-mail: nulrich@fhcr.org.

<sup>2</sup> The abbreviations used are: TS, thymidylate synthase; THF, tetrahydrofolate; MTHFR, 5,10-methylenetetrahydrofolate reductase; *TSER*, thymidylate synthase enhancer region; OR, odds ratio; UTR, untranslated region.

Table 1 Selected characteristics of the study population in the Minnesota Cancer Prevention Research Unit Polyp Study

Characteristic	Adenomatous polyps (n = 523)	Controls (n = 625)
Age <sup>a</sup> (years)	58.0 ± 9.7 (31–74)	52.9 ± 11.0 (30–74)
Sex		
Men	62%	38%
Women	38%	62%
Race/ethnicity		
Caucasian	98%	97%
Other <sup>b</sup>	2%	3%
Thymidylate synthase genotypes		
TSER polymorphism		
3rpt/3rpt	30%	26%
3rpt/2rpt	49%	52%
2rpt/2rpt (decreased expression)	21%	21%
2rpt/4rpt		0.3% <sup>c</sup>
3'UTR polymorphism		
6bp/6bp	45%	50%
6bp/0bp	44%	40%
0bp/0bp	11%	10%

<sup>a</sup> Mean ± SD (range).<sup>b</sup> Not included in further analyses.<sup>c</sup> Not Caucasian, not included in further analyses.

amplified fragments were separated on a 3% NuSieve agarose gel (BioWhittaker, Rockland, ME). The fragment containing three and two repeats were 243 and 215 bp, respectively.

The 3'UTR polymorphism was analyzed by RFLP as described (12). Briefly, a fragment containing the 6-bp deletion was amplified using primers 5'-CAAATCTGAGGGAGCTGAGT-3' and 5'-CAGATAAGTGGCAGTACAGA-3' in a reaction containing 1 × GeneAmp buffer, 2.5 mM MgCl<sub>2</sub>, 150 mM deoxyribonucleotide triphosphates, 300 nM each primer, 1 unit of AmpliTaq DNA polymerase, and 100 ng of genomic DNA. The cycling conditions were 1 cycle of 94°C for 5 min, 30 cycles of 94°C for 30 s, 58°C for 45 s, and 72°C for 45 s, and a final extension at 72°C for 5 min. The amplified fragments were digested with *DraI*, and the products were separated on a 3% NuSieve agarose gel. The expected fragment sizes were 70 and 88 bp for the wild-type allele and 152 bp for the variant allele.

**Statistical Data Analysis.** Unconditional logistic regression models were used to obtain maximum likelihood estimates, ORs, and 95% confidence intervals. Multivariate adjustment included age, sex, body mass index (kg/m<sup>2</sup>), percentage of calories from fat, hormone replacement therapy (ever/never), and pack-years of smoking. These variables altered some risk estimates by >10%. In general, confounding effects were small and often only apparent in stratified analyses; nonetheless, a consistent multivariate adjustment was maintained throughout all analyses presented. Other factors evaluated but not found to be confounders were waist:hip ratio, regular use of aspirin or nonsteroidal anti-inflammatory drugs (at least once/week versus never), hours of physical activity, and the dietary intake variables kcal, dietary fiber, vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, and alcohol. The *MTHFR* C677T polymorphism was also not found to confound the associations.

Effect modification of the relation between nutrient intakes and risk of adenomas by genotype was evaluated by testing for different slopes with increasing nutrient intake across genotypes. Because the allele frequency of the TSER polymorphism is known to vary by race (10), we restricted the study population to Caucasians (who comprised 97% of the original population) for a sample size of 510 cases and 604 controls. All tests of statistical significance

were two sided. SAS, version 8.2 (SAS Institute Inc., Cary, NC), was used for the analyses.

## Results

The study population and their dietary intakes have been described previously (15), and selected characteristics are presented in Table 1. The allele frequency of the TSER polymorphism among the controls was 0.48 with 52% heterozygotes (2rpt/3rpt) and 21% homozygous variant (2rpt/2rpt). The allele frequency of the TS 1494 6-bp deletion was 0.30 with 40% heterozygotes (6 bp/0 bp) and 10% homozygous variant (0 bp/0 bp). The two polymorphisms were in linkage disequilibrium: among those with a TSER 3rpt/3rpt genotype, 29% were found to have the TS 6 bp/6 bp genotype and 26% the 0 bp/0 bp genotype; among individuals with a TSER 2rpt/2rpt genotype, these proportions were 73 and 3%, respectively ( $P < 0.001$ ). However, all genotype combinations were observed. Both variants were in Hardy-Weinberg equilibrium.

**TSER Polymorphism.** Multivariate adjusted ORs (95% confidence interval) for 2rpt/3rpt and 2rpt/2rpt compared with 3rpt/3rpt were 0.8 (0.6–1.2) and 0.9 (0.6–1.3), respectively. Risk estimates were similar among men and women and among individuals either greater than age 60 or younger. As shown in Table 2 and Fig. 1, we observed a statistically significant gene-nutrient interaction with dietary folate intake: among individuals with the 3rpt/3rpt genotype, folate intake > 440 μg/day (highest tertile) versus ≤440 μg/day was associated with a 2-fold decreased risk [ORs 1 (ref; low intake) versus 0.5 (0.3–0.9; high intake)]. However, among individuals with the 2rpt/2rpt variant, a 1.5-fold increased risk associated with high folate intake was observed [ORs 0.6 (0.4–0.9) versus 0.9 (0.5–1.5);  $P$  for interaction = 0.03]. A similar trend was observed for vitamin B<sub>12</sub> intake: among individuals with the 3rpt/3rpt and 2rpt/3rpt genotypes, risk was reduced 2-fold with intakes in the highest tertile (≥9.78 μg/day, compared with <9.78 μg/day), whereas a slight increase in risk (1.3-fold) with intakes ≥ 9.78 μg/day was observed among individuals with the 2rpt/2rpt genotype ( $P$  for interaction = 0.08). Folate intake did not confound this association, nor did vitamin B<sub>12</sub> confound the folate/TS association. The associations with the TS polymorphism did not differ by intakes of vitamin B<sub>6</sub>, methionine, or alcohol (data not shown).


Because we have shown previously that the *MTHFR* C677T polymorphism affects risk of adenomas in this population (15), we stratified the analysis further by *MTHFR* genotype (Table 3). Although the cell sizes are small, and the results should be considered exploratory, some trends are suggested: (a) the decrease in risk associated with high folate intakes was again confined to individuals with greater TS expression (3rpt/3rpt genotype), irrespective of *MTHFR* genotype; and (b) the previously reported increase in adenoma risk associated with low folate intake among individuals with the *MTHFR* TT genotype (15, 16) was only seen among those with the 3rpt/3rpt genotype (>3-fold). Lower TS expression (2rpt/3rpt or 2rpt/2rpt genotypes)

Table 2 Association between the TSER polymorphism and adenomatous polyps—stratified by dietary intakes of folate and vitamin B<sub>12</sub><sup>a</sup>

Nutrient intakes from both diet and supplements	(n cases/n controls)	TSER genotype			P for interaction <sup>b</sup>
		3rpt/3rpt	3rpt/2rpt	2rpt/2rpt	
Folate					
Low/medium	347/381	1.0 (ref)	0.70 (0.48–1.02)	0.58 (0.36–0.94)	
High	158/207	0.53 (0.31–0.91)	0.63 (0.40–0.99)	0.88 (0.51–1.53)	$P = 0.03$
Vitamin B <sub>12</sub>					
Low/medium	354/382	1.0 (ref)	0.75 (0.52–1.10)	0.62 (0.39–1.00)	
High	151/206	0.52 (0.31–0.90)	0.51 (0.33–0.81)	0.82 (0.45–1.49)	$P = 0.08$

<sup>a</sup> Multivariate adjustment for age, sex, body mass index, hormone replacement therapy (y/n), percentage of kcal from fat, and pack-years of smoking.<sup>b</sup> Testing for different slopes associated with nutrient intake across genotypes. Cutpoints for dietary intakes: folate (440 μg) and vitamin B<sub>12</sub> (9.78 μg).

1A) TSER polymorphism and folate intake



1B) TSER polymorphism and vitamin B<sub>12</sub> intake




Fig. 1. Risk of colorectal polyps associated with the TSER polymorphism, stratified by folate (A) or vitamin B-12 (B) intake.

appeared to be inversely associated with risk under conditions of low-folate intakes, most prominently so among individuals with the *MTHFR* TT genotype. When folate intakes were not considered, the combination of a TSER 2rpt/2rpt genotype and *MTHFR* TT genotype was the lowest risk group compared with all other genotype combinations (data not shown).

**TS 1494del6 Polymorphism.** The *TS* 6-bp deletion polymorphism at bp 1494 in the 3'UTR was not associated significantly with risk of colorectal adenomas [compared with 6bp/6bp wild-type OR = 1 (reference): 6bp/0bp OR = 1.22 (0.93–1.61); 0 bp/0 bp OR = 1.13 (0.73–1.74)]. When stratified by dietary intakes of folate or vitamin B<sub>12</sub>, or by *MTHFR* genotype, no consistent patterns were apparent (data not shown). Although one might expect results similar to those for the *TSER* polymorphism, because of linkage between the two polymorphisms, these findings illustrate that “imperfect” disequilibrium may result in different associations with disease phenotypes. Adjustment for the *TSER* polymorphism did not modify the associations. We investigated the risk of adenomas associated with all possible *TSER/TS* 1494del6 genotype combinations, and none of the risks was statistically different from 1 (with a *TSER* 3rpt/3rpt *TS* 6bp/6bp genotype as referent; data not shown).

Discussion

To our knowledge, this is the first study investigating the relevance of *TS* polymorphisms in colorectal carcinogenesis. As with other polymorphisms in folate metabolism (15, 17), upon stratification by a relevant exposure (folate), an informative pattern emerged. We observed a statistically significant gene environment interaction, with a

decreased adenoma risk associated with high folate intakes among individuals with the *TSER* wild-type (3rpt/3rpt) genotype and the opposite association (increased risk with high folate intake) among individuals with lower *TS* expression (2rpt/2rpt). Similar trends were observed for vitamin B-12 intake, which is an essential cofactor for another key enzyme in folate metabolism, methionine synthase.

Under low or medium folate intakes and in the presence of a *MTHFR* TT genotype, which can be considered to further impair folate status, the *TSER* variant genotypes were associated with a decreased risk of colorectal adenoma. Thus, we hypothesize that the lower *TS* expression (2rpt/2rpt or 3rpt/2rpt genotypes) may have a “folate-sparing” effect that reduces risk of adenoma.

The finding of a decreased risk associated with lower *TS* expression in the presence of low-folate intake (Fig. 1) was unexpected. Previously, several groups have hypothesized that the inverse association between the C677T *MTHFR* polymorphism and colorectal carcinogenesis may be attributable to a greater diversion of the relevant substrate (5,10-methylene-THF toward nucleotide synthesis; *TS* and several enzymes involved in purine synthesis; Refs. 15, 17, and 18). *TS* converts dUMP to dTMP, and it has been shown that folate deficiency can lead to uracil misincorporation associated with an increased risk of double-strand breaks (4, 5). Our findings, however, suggest that the purine synthesis pathway may be a relevant mechanism linking folate metabolism to colorectal carcinogenesis.

Two potential explanations could reconcile our findings with the existing knowledge about this pathway: (a) it is likely that, within the folate pathway, a balance exists between the provision of 5,10-methylene-THF for thymidine synthesis, purine synthesis, and the provision of methyl groups for methylation reactions. On the basis of biochemical models in pig liver, the cellular concentration of 5,10-methylene-THF regulates the flux of this metabolite into the pathways leading to nucleotide synthesis and methionine regeneration (19). It is unclear whether variations in enzyme function could affect these regulatory mechanisms; and (b) it may be that an adequate provision of 5,10-methylene-THF for purine synthesis is key. Depurination is the most common form of spontaneous DNA damage, with an estimated 10,000 depurinations/cell/day (20, 21). Although an abundance of apurinic endonucleases efficiently repairs this damage, quantitative measurements show that abasic sites are present in cellular DNA, with a steady-state level of 5–10,000 lesions/cell/day (21). Thus, depurination may be the major challenge the body faces on a continuous basis, and the provision of an adequate supply of purines may be an important prerequisite for repair. Accordingly, in the presence of low folate, it may be that purine synthesis is the most protected pathway.

Perturbations of nucleotide pools attributable to folate deficiency have been associated with inhibited DNA repair and increased mutation rates (1, 2). However, the role of purine depletion in mutagenesis

Table 3 Association between *TS* genotypes and adenomatous polyps—stratified by *MTHFR* C677T genotypes and folate intake<sup>a</sup>

(n cases/n controls)	<i>TSER</i> polymorphism	
	3rpt/3rpt	3rpt/2rpt or 2rpt/2rpt
<i>MTHFR</i> C677T polymorphism		
CC		
Low/medium folate	168/182	1.81 (1.07–3.06)
High folate	76/95	0.91 (0.49–1.71)
CT		
Low/medium folate	145/160	1.15 (0.65–2.02)
High folate	62/81	0.74 (0.32–1.68)
TT		
Low/medium folate	31/38	2.22 (0.85–5.84)
High folate	19/30	0.60 (0.14–2.50)

<sup>a</sup> Multivariate adjustment for age, sex, body mass index, hormone replacement therapy (y/n), percentage of kcal from fat, and pack-years of smoking. Cutpoints for dietary intakes: folate (440 μg), vitamin B<sub>12</sub> (9.78 μg), and vitamin B<sub>6</sub> (3.17 mg).

is unclear. There is no evidence that folate deficiency results in a greater prevalence of apurinic sites, but, to our knowledge, this has not yet been investigated. An effect of folate deficiency on purine pools has been documented in one study (22). The most promising evidence in support of a link between folate deficiency, purine synthesis, and DNA damage stems from investigations in an *in vitro* model of folate-deficient erythropoiesis, indicating that decreased *de novo* synthesis of purines plays an equally important role as decreased *de novo* synthesis of thymidylate in the pathogenesis of megaloblastic anemia (23).

Our study had several limitations. The study population was comprised of individuals undergoing screening by colonoscopy and was thus not necessarily representative of the general population. The major advantage of this clinic-based approach, nonetheless, is the unambiguous distinction between patients with adenomas and polyp-free controls. The indications for colonoscopy were not related to the TS genotype or to intakes of the nutrients investigated. Thus, a bias attributable to differences in indication for colonoscopy is unlikely. A strength of the study is the relatively large study size, permitting us to investigate gene-nutrient interactions. However, for analyses investigating genotype combinations (*MTHFR* and TS) in conjunction with nutritional status, our statistical power was limited.

In summary, previous research on *MTHFR* polymorphisms has illustrated the importance of genetic variability in the folate pathway in colorectal carcinogenesis. We here extend these findings to a common polymorphism in TS, which modifies risk depending on folate status (and possibly vitamin B-12 status). Our findings raise questions regarding the molecular pathways linking folate metabolism to colorectal carcinogenesis, especially including whether folate is beneficial in the presence of all metabolic genotypes. It may also have implications for the pharmacogenetics of antifolate drugs, such as 5-fluorouracil.

### Acknowledgments

We thank Angela Bush for technical assistance with the DNA genotyping, Rachel Sparks for general research assistance, and Mari Nakayoshi for assistance with graphics and word processing.

### References

- James, S. J., Basnakian, A. G., and Miller, B. J. *In vitro* folate deficiency induces deoxynucleotide pool imbalance, apoptosis, and mutagenesis in Chinese hamster ovary cells. *Cancer Res.*, *54*: 5075–5080, 1994.
- Snyder, R. D. Effects of nucleotide pool imbalances on the excision repair of ultraviolet-induced damage in the DNA of human diploid fibroblasts. *Basic Life Sci.*, *31*: 163–173, 1985.
- Mattano, S. S., Palella, T. D., and Mitchell, B. S. Mutations induced at the hypoxanthine-guanine phosphoribosyltransferase locus of human T-lymphoblasts by perturbations of purine deoxyribonucleoside triphosphate pools. *Cancer Res.*, *50*: 4566–4571, 1990.
- Duthie, S. J. Folic acid deficiency and cancer: mechanisms of DNA instability. *Br. Med. Bull.*, *55*: 578–592, 1999.
- Fenech, M. The role of folic acid and Vitamin B12 in genomic stability of human cells. *Mutat. Res.*, *475*: 57–67, 2001.
- Potter, J. D. Colorectal cancer: molecules and populations. *J. Natl. Cancer Inst.*, *91*: 916–932, 1999.
- Choi, S. W., and Mason, J. B. Folate and carcinogenesis: an integrated scheme. *J. Nutr.*, *130*: 129–132, 2000.
- Kaneda, S., Takeishi, K., Ayusawa, D., Shimizu, K., Seno, T., and Altman, S. Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA. *Nucleic Acids Res.*, *15*: 1259–1270, 1987.
- Horie, N., Aiba, H., Oguro, K., Hojo, H., and Takeishi, K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. *Cell Struct. Funct.*, *20*: 191–197, 1995.
- Marsh, S., Collie-Duguid, E. S., Li, T., Liu, X., and McLeod, H. L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. *Genomics*, *58*: 310–312, 1999.
- Pullarkat, S. T., Stoehlmacher, J., Ghaderi, V., Xiong, Y.-P., Ingles, S. A., Sherrod, A., Warren, R., Tsao-Wei, D., Groshen, S., and Lenz, H.-J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. *Pharmacogenomics*, *1*: 65–70, 2001.
- Ulrich, C., Bigler, J., Velicer, C., Greene, E., Farin, F., and Potter, J. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. *Cancer Epidemiol. Biomark. Prev.*, *9*: 1381–1385, 2000.
- Lenz, H.-J., Zhang, W., Zhahedy, S., Gil, J., Yu, M., and Stoehlmacher, J. A 6 base-pair deletion in the 3'UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors. A possible candidate gene for colorectal cancer risk. *Proc. AACR*, *43*: 660, 2002.
- Potter, J. D., Bostick, R. M., Grandits, G. A., Fosdick, L., Elmer, P., Wood, J., Grambsch, P., and Louis, T. A. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. *Cancer Epidemiol. Biomark. Prev.*, *5*: 779–784, 1996.
- Ulrich, C. M., Kampman, E., Bigler, J., Schwartz, S. M., Chen, C., Bostick, R., Fosdick, L., Beresford, S. A., Yasui, Y., and Potter, J. D. Colorectal adenomas and the C677T *MTHFR* polymorphism: evidence for gene-environment interaction? *Cancer Epidemiol. Biomark. Prev.*, *8*: 659–668, 1999.
- Levine, A. J., Siegmund, K. D., Ervin, C. M., Diep, A., Lee, E. R., Frankl, H. D., and Haile, R. W. The methylenetetrahydrofolate reductase 677C→T polymorphism and distal colorectal adenoma risk. *Cancer Epidemiol. Biomark. Prev.*, *9*: 657–663, 2000.
- Ma, J., Stampfer, M. J., Giovannucci, E., Artigas, C., Hunter, D. J., Fuchs, C., Willett, W. C., Selhub, J., Hennekens, C. H., and Rozen, R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. *Cancer Res.*, *57*: 1098–1102, 1997.
- Chen, J., Giovannucci, E. L., and Hunter, D. J. *MTHFR* polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U. S. men and women: an example of gene-environment interactions in colorectal tumorigenesis. *J. Nutr.*, *129*: 560S–564S, 1999.
- Green, J. M., MacKenzie, R. E., and Matthews, R. G. Substrate flux through methylenetetrahydrofolate dehydrogenase: predicted effects of the concentration of methylenetetrahydrofolate on its partitioning into pathways leading to nucleotide biosynthesis or methionine regeneration. *Biochemistry*, *27*: 8014–8022, 1988.
- Lindahl, T., and Nyberg, B. Rate of depurination of native deoxyribonucleic acid. *Biochemistry*, *11*: 3610–3618, 1972.
- Nakamura, J., and Swenberg, J. A. Endogenous apurinic/aprimidinic sites in genomic DNA of mammalian tissues. *Cancer Res.*, *59*: 2522–2526, 1999.
- Walzem, R. L., Clifford, C. K., and Clifford, A. J. Purine synthesis and reutilization in folate-deficient rat hepatocytes. *J. Nutr.*, *113*: 1032–1038, 1983.
- Koury, M. J., Price, J. O., and Hicks, G. G. Apoptosis in megaloblastic anemia occurs during DNA synthesis by a p53-independent, nucleoside-reversible mechanism. *Blood*, *96*: 3249–3255, 2000.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## ***Thymidylate Synthase Promoter Polymorphism, Interaction with Folate Intake, and Risk of Colorectal Adenomas***

Cornelia M. Ulrich, Jeannette Bigler, Roberd Bostick, et al.

*Cancer Res* 2002;62:3361-3364.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/62/12/3361>

**Cited articles** This article cites 20 articles, 10 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/62/12/3361.full#ref-list-1>

**Citing articles** This article has been cited by 30 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/62/12/3361.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/62/12/3361>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.